Roquefort Therapeutics (LON:COIL) Trading Up 7.9% – Here’s Why

Roquefort Therapeutics plc (LON:COIL)’s share price traded up 7.9% during mid-day trading on Monday . The stock traded as high as GBX 8.90 and last traded at GBX 8.90. 314,041 shares traded hands during trading, an increase of 74% from the average session volume of 180,045 shares. The stock had previously closed at GBX 8.25.

Roquefort Therapeutics Stock Performance

The stock has a market cap of £36.20 million, a P/E ratio of -1.35 and a beta of 0.05. The company has a debt-to-equity ratio of 8.07, a current ratio of 2.80 and a quick ratio of 3.07. The firm’s 50-day moving average price is GBX 8.80 and its 200-day moving average price is GBX 12.16.

Roquefort Therapeutics (LON:COIL) last released its quarterly earnings data on Wednesday, May 6th. The company reported GBX (2.19) earnings per share (EPS) for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 18.30%.

Roquefort Therapeutics Company Profile

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.